Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHLIA: Danirixin + Oseltamivir in Hospitalized Influenza
NCT02927431Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of danirixin in influenza (3 arms), sponsored by GSK. Primary endpoint: Time to Clinical Response up to 45 Days. Started Jan 2017; status: terminated.
02
Drugs
danirixin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02927431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927431.